Stroke RSS Page 2

Filtered By:
Source: Thrombosis and Haemostasis

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 528 results found since Jan 2013.

Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
CONCLUSION: There is a low rate of recurrent VTE but significant end-organ morbidity in infants with unprovoked VTE.PMID:37538506 | PMC:PMC10394551 | DOI:10.1016/j.rpth.2023.100174
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Hilary Whitworth Lauren A Beslow Rebecca A Hubbard Charles E Leonard Rebecca Scobell Char Witmer Leslie Raffini Source Type: research

Thrombus composition and thrombolysis resistance in stroke
Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May.ABSTRACTA State of the Art lecture titled "Thrombus Composition and Thrombolysis Resistance in Stroke" was presented at the ISTH Congress in 2022. Intravenous thrombolysis (IVT) remains the only pharmacologic option to re-establish cerebral perfusion at the acute phase of ischemic stroke. IVT is based on the administration of recombinant tissue plasminogen activator with the objective of dissolving fibrin, the major fibrillar protein component of thrombi. Almost 30 years on from its introduction, although the clinical b...
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Benoit Ho-Tin-No é Jean-Philippe Desilles Mikael Mazighi Source Type: research

Hypercoagulability State in Predicting Severe Functional Outcome in Patients with Acute Ischemic Stroke: Cause, Consequence, or Both?
Thromb Haemost. 2023 Jul 10. doi: 10.1055/s-0043-1771029. Online ahead of print.NO ABSTRACTPMID:37429564 | DOI:10.1055/s-0043-1771029
Source: Thrombosis and Haemostasis - July 10, 2023 Category: Hematology Authors: Maurizio Paciaroni Source Type: research

Warfarin faring better: Vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials
J Thromb Haemost. 2023 Jul 8:S1538-7836(23)00523-8. doi: 10.1016/j.jtha.2023.06.036. Online ahead of print.ABSTRACTAlthough guidelines give preference to the direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or mechanical heart valves. The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease associated AF, and the PR...
Source: Thrombosis and Haemostasis - July 10, 2023 Category: Hematology Authors: John W Eikelboom Jeffrey I Weitz Source Type: research

Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
CONCLUSION: In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.PMID:37399842 | DOI:10.1055/s-0043-1770724
Source: Thrombosis and Haemostasis - July 3, 2023 Category: Hematology Authors: Yuxiang Zheng Siyuan Li Xiao Liu Gregory Y H Lip Linjuan Guo Wengen Zhu Source Type: research

Survey on APS diagnosis and antithrombotic treatment in patients with ischaemic stroke, other brain ischaemic injury or arterial thromboembolism in other sites: Communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies (LA/aPL)
CONCLUSIONS: Much of the variation in practice reflects the lack of evidence-based recommendations. The survey results should inform the development of a more uniform multidisciplinary consensus approach to diagnosis and antithrombotic treatment.PMID:37391096 | DOI:10.1016/j.jtha.2023.06.020
Source: Thrombosis and Haemostasis - June 30, 2023 Category: Hematology Authors: Hannah Cohen David J Werring Arvind Chandretheva Prabal Mittal Katrien M J Devreese David A Isenberg ISTH SSC LA/aPL Subcommittee Study Group Source Type: research

The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
CONCLUSION: Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.PMID:37369234 | DOI:10.1055/s-0043-1769735
Source: Thrombosis and Haemostasis - June 27, 2023 Category: Hematology Authors: Maxim Grymonprez Mirko Petrovic Tine L De Backer Stephane Steurbaut Lies Lahousse Source Type: research

Coagulation biomarkers for ischemic stroke
We report on coagulation biomarker-induced risk of IS, stroke severity, and outcomes following IS derived from prospective population studies, case-control studies, and acute-phase IS studies. We found indications that many coagulation and inflammation biomarkers are associated with IS, but it is early to conclude that any of these biomarkers can be applied in a therapeutic setting to predict patients at risk of IS, stroke severity at the acute phase, and clinical outcome after treatment. The strongest evidence for a role in IS was found for beta-thromboglobulin, von Willebrand factor, factor VIII, fibrinogen, thrombin-act...
Source: Thrombosis and Haemostasis - June 5, 2023 Category: Hematology Authors: Aarazo Barakzie A J Gerard Jansen Hugo Ten Cate Moniek P M de Maat Source Type: research

Poststroke venous thromboembolism and neutrophil activation: an illustrated review
Res Pract Thromb Haemost. 2023 Apr 29;7(4):100170. doi: 10.1016/j.rpth.2023.100170. eCollection 2023 May.ABSTRACTPatients with acute ischemic stroke are at a high risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT), estimated to affect approximately 80,000 patients with stroke each year in the United States. The prevalence of symptomatic DVT after acute stroke is approximately 10%. VTE is associated with increased rates of in-hospital death and disability, with higher prevalence of in-hospital complications and increased 1-year mortality in patients with stroke. Current guidelines recommend the use of ...
Source: Thrombosis and Haemostasis - June 5, 2023 Category: Hematology Authors: Nirav Dhanesha Junaid Ansari Nilesh Pandey Harpreet Kaur Chiranjiv Virk Karen Y Stokes Source Type: research

Thrombotic Complications in Children with COVID-19 and MIS-C
J Thromb Haemost. 2023 May 31:S1538-7836(23)00434-8. doi: 10.1016/j.jtha.2023.05.020. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet activation and impaired fibrinolysis. Hospitalized adults with COVID-19 are at an increased risk of both venous thrombo-embolism (VTE) and ischemic stroke, resulting in adverse outcomes including mortality. While children with COVID-19 follow a less severe course, both arterial and venous thrombosis have been reported in hospitalized children with...
Source: Thrombosis and Haemostasis - June 2, 2023 Category: Hematology Authors: Riten Kumar Michael J Rivkin Leslie Raffini Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20